MOBILE, Ala. / Oct 31, 2025 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and community healthcare organizations, today announced that it will release its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the market closes. The Company will host a conference call at 7:30 a.m. Central Time, 8:30 a.m. Eastern Time on Friday, November 7, 2025. To access this interactive teleconference, dial (877) 407-0890 and request connection to the TruBridge earnings conference call.
A live broadcast of TruBridge’s conference call will also be available online at the Company’s investor relations website, investors.trubridge.com. The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About TruBridge
TruBridge proudly supports rural and community healthcare providers in their efforts to stay strong, independent, and deeply rooted in the communities they serve. Backed by more than 45 years of healthcare experience and trusted by over 1,500 clients nationwide, we offer a mix of technology, services, and strategic expertise — including revenue cycle management (RCM), electronic health records (EHR) and analytics — all designed singularly for the realities of rural and community healthcare. With a steadfast commitment to keeping care local, TruBridge helps hospitals flourish as the economic heart of their communities, delivering high-quality, deeply personal care close to home.
| Last Trade: | US$22.36 |
| Daily Change: | -0.43 -1.89 |
| Daily Volume: | 105,118 |
| Market Cap: | US$335.620M |
November 06, 2025 October 03, 2025 September 23, 2025 August 07, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load